600572 Zhejiang Conba Pharmaceutical
- 5.18
- +0.05+0.97%
Zhejiang Conba Pharmaceutical News
Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Express News | Kangenbei's innovative traditional Chinese medicine yellow holly flower flavonoid oral patch received a reward of 10 million yuan from the government
Conn Bay (600572.SH)'s net profit of 216 million yuan in the first quarter decreased by 23.98% year-on-year
On April 26, Ge Longhui (600572.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,824 million yuan, a year-on-year decrease of 14.38%; net profit attributable to shareholders of listed companies was 216 million yuan, a year-on-year decrease of 23.98%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 201 million yuan, a year-on-year decrease of 23.57%; and basic earnings per share were 0.084 yuan.
Guoyuan Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating. The main reasons for the rating include: 1) Performance growth is in line with expectations, and the overall business trend continues t
Guoyuan Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating. The main reasons for the rating include: 1) Performance growth is in line with expectations, and the overall business trend continues to improve; 2) Innovative R&D continues to accelerate, and future growth momentum is sufficient. (Mainichi Keizai Shimbun)
SDIC Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating and the target price was 7.00 yuan. The main reasons for the rating include: 1) the performance is in line with expectations, and the busin
SDIC Securities released a research report on April 24 stating that it gave Kangenbei (600572.SH) a purchase rating and the target price was 7.00 yuan. The main reasons for the rating include: 1) the performance is in line with expectations, and the business classification criteria are adjusted according to the development strategy; 2) adhering to the “big variety, big brand” strategy, the core product, the Changyan Ning series, has grown brilliantly. (Mainichi Keizai Shimbun)
Conn Bay (600572) 2023 Annual Report Review: Main business focuses on accelerating steady growth in performance
Incident: The company released the 2023 annual report, achieving operating income of 6.733 billion yuan, a year-on-year increase of 12.20%; net profit to mother of 592 million yuan, an increase of 65.19% over the previous year; net profit after deduction of 5.54 billion yuan
Kangenbei (600572): Steady growth in performance, accelerated development of traditional Chinese medicine health business
Incident: The company released its 2023 annual report. The full year of 2023 achieved revenue of 6.733 billion yuan (yoy +12.21%), net profit of 592 million yuan (yoy +65.19%), deducted from non-return to mother
Conn Bay (600572): Steady growth in performance, “improving quality, efficiency, and heavy return” promotes high corporate dividends
On April 19, 2024, Conn Bay disclosed its annual report: in 2023, the company achieved operating income of 6.733 billion yuan, +12.20% year over year; realized net profit to mother of 592 million yuan, +65.19% year over year
Guojin Securities released a research report on April 22 stating that it gave Kangenbei (600572.SH) an increase in its holdings. The main reasons for the rating include: 1) product structure optimization, healthy growth in the core business of Traditional
Guojin Securities released a research report on April 22 stating that it gave Kangenbei (600572.SH) an increase in its holdings. The main reasons for the rating include: 1) product structure optimization, healthy growth in the core business of Traditional Chinese Medicine Health; 2) remarkable brand building results, continued expansion of large brands and large varieties; 3) focusing on the main business and continuing to promote resource integration. (Mainichi Keizai Shimbun)
Connbey (600572): Stable and progressive performance in 2023, “two wings in one” are poised to break through again
Incident: The company released its 2023 annual report. The company achieved operating income of 6.733 billion yuan (yoy +12%) in 2023, net profit of 554 million yuan after deducting non-return to mother (yoy +15%), and net profit to mother5
Kangenbei (600572): Adhere to the “Big Variety, Big Brand” Strategy to Improve Quality, Increase Efficiency, and Value Returns
Event: On April 19, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 6.733 billion yuan, an increase of 12.21% over the previous year, and achieved net profit of 592 million yuan to mother
Conn Bay (600572): Big brands, big varieties, outstanding performance, R&D empowers future development
In 2023, the company achieved revenue of 6.733 billion yuan (YoY +12.21%), net profit attributable to mother of 592 million yuan (YoY +65.20%), net profit not attributable to mother of 554 million yuan (YoY +14.60%)
Conn Bay (600572): Focus on the main business strategy, and have achieved remarkable results in brand building
Performance Brief Review On April 19, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 6.73 billion yuan, +12.2% year-on-year; net profit to mother was 590 million yuan, +65 yuan year-on-year.
Conn Bay (600572.SH) announced its 2023 annual results, with net profit of 592 million yuan, an increase of 65.19%
Conn Bay (600572.SH) released its 2023 annual report. The company's revenue was 6.733 billion yuan...
Are Strong Financial Prospects The Force That Is Driving The Momentum In Zhejiang CONBA Pharmaceutical Co.,Ltd.'s SHSE:600572) Stock?
Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) has had a great run on the share market with its stock up by a significant 10% over the last three months. Since the market usually pay for a company's
Guojin Securities released a research report on April 9 stating that Connbe (600572.SH) was given an increase in holdings rating, and the target price was 5.40 yuan. The main reasons for the rating include: 1) the company uses modern traditional Chinese m
Guojin Securities released a research report on April 9 stating that Connbe (600572.SH) was given an increase in holdings rating, and the target price was 5.40 yuan. The main reasons for the rating include: 1) the company uses modern traditional Chinese medicine and botanicals as the core, and continues to promote large-scale projects for big brands; 2) the mixed reform helps the company strengthen resource integration, and actual controllers increase their confidence in development; 3) focus on developing the self-care product business and optimizing the business structure; 4) multiple varieties in the prescription medicine sector have entered medical insurance, which is expected to be released at a high speed. (Mainichi Keizai Shimbun)
In-depth research by Kangenbei (600572): The growth trend of key varieties with mixed reform to improve quality and efficiency is good
With modern traditional Chinese medicine and botanical medicine as the core, Investment Logic Company continues to promote large-scale projects for big brands. After years of development, the company formed business segments such as non-prescription drugs, prescription drugs, health consumer goods, Chinese medicine tablets, etc., with a total of 15 in 2022
Conn Bay (600572.SH) has repurchased a total of 1% of its shares at a cost of 120 million yuan
Conn Bay (600572.SH) announced that as of March 29, 2024, the company passed the Shanghai Stock Exchange...
Express News | Shares of 7 listed companies were increased by important shareholders, and Connbey increased their holdings by the highest amount
The controlling shareholders of Kangenbei (600572.SH) increased their total shares by 2%
Conn Bay (600572.SH) issued an announcement from January 31, 2024 to March 22, 2024...
Analysis
Price Target
No Data
